IP Library Granted Patent US 10,272,148
Granted Patent B2
US 10,272,148 · App. 13/380,346 · Granted Apr 30, 2019

Chimeric influenza virus-like particles comprising hemagglutinin

Inventors: Manon Couture (St-Augustin-de-Desmaures, CA); Michele Dargis (Quebec, CA); Pierre-Olivier Lavoie (Quebec, CA); Louis-Philippe Vezina (Neuville, CA); Marc-Andre D'Aoust (Quebec, CA)
Assignee: MEDICAGO INC.
A61K39/145A61K39/12C07K14/005C12N15/8257A61K2039/5258C07K2319/00C07K2319/02C12N2760/16122C12N2760/16123C12N2760/16134C12N2760/16222C12N2760/16223C12N2760/16234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,272,148
App. No.
13/380,346
Granted
Apr 30, 2019
Kind
B2
Abstract

A method for synthesizing chimeric influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of chimeric influenza HA in a plant or a portion of a plant. The invention is also directed towards a VLP comprising chimeric influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding chimeric influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.

Claims (38)

1. A nucleic acid comprising one or more regulatory regions comprising a promoter, the promoter recognized by RNA polymerase 2 and operatively linked to a sequence encoding a chimeric influenza hemagglutinin (HA) polypeptide comprising a stem domain cluster (SDC), a head domain cluster (HDC) and a transmembrane domain cluster (TDC), the one or more regulatory regions further including a 5′UTR and 3′UTR, and wherein

a) the SDC comprises an F′1, F′2 and F subdomain;

b) the HDC comprises receptor binding (RB) subdomain, vestigial esterase subdomain E1 (E1) and vestigial esterase subdomain E2 (E2);

c) the TDC comprises a transmembrane (TmD) and C terminal tail (CT) subdomain; and

wherein the RB subdomain is of a first influenza HA polypeptide, the SDC, the E1, the E2, and the TDC subdomains are from a second influenza HA polypeptide, and wherein the first influenza HA polypeptide is from influenza H1 or H5, and the second influenza HA polypeptide is from influenza H1 or H5, and the second influenza HA is derived from a different influenza strain than the first influenza polypeptide, wherein the F′1 subdomain is fused to a native or plant derived signal peptide, and the 3′UTR and 5′UTR is heterologous to the first, and the second, influenza HA.

2. The nucleic acid of claim 1 , wherein the sequence encoding a chimeric influenza HA polypeptide further comprises a signal peptide sequence selected from the group consisting of an HA native signal peptide sequence, and an alfalfa PDI signal peptide sequence.

3. The nucleic acid of claim 1 , wherein the 5′UTR and 3′UTR are obtained from a plastocyanin UTR or Cowpea Mosaic Virus (CPMV) UTR.

4. The nucleic acid of claim 1 , wherein the regulatory region is obtained from a plastocyanin regulatory region, a Ribulose 1,5-bisphosphate carboxylase/oxygenase (RuBisCO) regulatory region, a chlorophyll a/b binding protein (CAB) regulatory region, a CaMV 35S regulatory region, an actin regulatory region, a ubiquitin regulatory region, a triosephosphate isomerase 1 regulatory region, a translational initiation factor 4A regulatory region, or an ST-LSI regulatory region.

5. A method of producing chimeric influenza HA protein in a plant comprising:

a) introducing the nucleic acid of claim 1 into the plant, or portion thereof

b) incubating the plant, or portion thereof, under conditions that permit the expression of the nucleic acid, thereby producing the chimeric influenza HA protein; and

c) harvesting the plant and obtaining the chimeric influenza HA protein.

6. A polypeptide encoded by the nucleic acid of claim 1 .

7. The polypeptide of claim 6 further comprising plant-specific N-glycans or modified N-glycans.

8. A composition comprising an effective dose of the polypeptide of claim 7 and a pharmaceutically acceptable carrier.

9. A plant cell, comprising a polypeptide encoded by the nucleic acid of claim 1 .

10. A method of producing chimeric influenza virus like particles (VLPs) in a plant comprising:

a) introducing the nucleic acid of claim 3 into the plant, or portion thereof using agroinfiltration;

b) incubating the plant, or portion thereof, under conditions that permit the expression of the nucleic acid, thereby producing the chimeric VLPs; and

c) harvesting the plant and obtaining the chimeric VLPs.

11. A nucleic acid comprising one or more regulatory regions comprising a promoter, the promoter recognized by RNA polymerase 2 and operatively linked to a sequence encoding a chimeric influenza hemagglutinin (HA) polypeptide, the chimeric influenza HA polypeptide comprising a stem domain cluster (SDC), a head domain cluster (HDC) and a transmembrane domain cluster (TDC), the one or more regulatory regions further including a 5′UTR and 3′UTR,

wherein

a) the SDC comprises an F′1, F′2 and F subdomain;

b) the HDC comprises a receptor binding (RB) subdomain, vestigial esterase subdomain E1 (E1) and vestigial esterase subdomain E2 (E2);

c) the TDC comprises a transmembrane (TmD) and C terminal tail (CT) subdomain; and

wherein the HDC and SDC subdomain is obtained from influenza H3, H6 or B, and the TDC is obtained from influenza H1 or H5 wherein the F′1 subdomain is fused to a native or plant derived signal peptide, and the 3′UTR and 5′UTR is heterologous to the sequence encoding the influenza H1, H3, H5, H6 or B HA.

12. A method of producing chimeric influenza HA protein in a plant comprising:

a) introducing the nucleic acid of claim 11 into the plant, or portion thereof

b) incubating the plant, or portion thereof, under conditions that permit the expression of the nucleic acid, thereby producing the chimeric influenza HA protein; and

c) harvesting the plant and obtaining the chimeric influenza HA protein.

13. The nucleic acid of claim 2 wherein the HA native signal peptide sequence is selected from an influenza H5 signal peptide sequence and an influenza H1 signal peptide sequence.

14. A polypeptide encoded by the nucleic acid of claim 11 .

15. A plant cell comprising a polypeptide encoded by the nucleic acid of claim 11 .

16. The nucleic acid of claim 11 , wherein the 5′UTR and 3′UTR are obtained from a plastocyanin UTR or Cowpea Mosaic Virus (CPMV) UTR.

17. A method of producing chimeric influenza virus like particles (VLPs) in a plant comprising:

a) introducing the nucleic acid of claim 16 into the plant, or portion thereof using agroinfiltration;

b) incubating the plant, or portion thereof, under conditions that permit the expression of the nucleic acid, thereby producing the chimeric VLPs; and

c) harvesting the plant and obtaining the chimeric VLPs.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2024
From: MEDICAGO INC.
To: ARAMIS BIOTECHNOLOGIES INC.
Reel/Frame 069383/0271 →
CONFIRMING ASSIGNMENT Recorded Mar 19, 2012
From: COUTURE, MANON; DARGIS, MICHELE; LAVOIE, PIERRE-OLIVIER; VEZINA, LOUIS-PHILIPPE; D'AOUST, MARC-ANDRE
To: MEDICAGO INC.
Reel/Frame 027887/0071 →
Continuity (2)
Provisional Application 61220161 · Jun 24, 2009
Related Publication 20120189658A1 · Jul 26, 2012